Are Frexalimab, Brivekimig, and Rilzabrutinib being tested together to treat Focal Segmental Glomerulosclerosis?
Frexalimab, Brivekimig, and Rilzabrutinib are not being tested as a single combination therapy. Instead, a Phase 2 study is currently recruiting patients to test these drugs separately. The goal is to determine which single drug works best for reducing protein loss in the urine for people with Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD).
What the research says
A Phase 2a study led by Sanofi is designed as a parallel, double-blind trial with six different arms. This setup allows researchers to compare the effects of Frexalimab, Brivekimig, and Rilzabrutinib individually against a placebo. The study specifically looks at how much each drug reduces the urine protein to creatinine ratio and whether it helps patients achieve remission from nephrotic syndrome 4.
The trial enrolls adults aged 16 to 75 years with primary FSGS or primary MCD. Participants receive one of the study drugs or a placebo for up to 24 weeks. Researchers will monitor patients for up to 76 weeks total, with visits scheduled to track their progress. The primary goal is to identify if any of these single agents provide a significant benefit over the placebo in reducing proteinuria 4.
Other research highlights different treatment approaches for FSGS. For example, studies have looked at Rituximab for reducing relapses in pediatric patients with FSGS, though results vary between subtypes of the disease 1. Another case report described a patient with FSGS who achieved remission after switching from Rituximab to Obinutuzumab, a different type of antibody therapy 2. Additionally, researchers are studying Acthar in patients who have received kidney transplants to prevent the recurrence of FSGS 3.
What to ask your doctor
- Am I a candidate for the upcoming Phase 2 study testing Frexalimab, Brivekimig, or Rilzabrutinib?
- What are the potential side effects of Frexalimab, Brivekimig, or Rilzabrutinib compared to my current treatment?
- How will my doctor decide which single drug is the best option for my specific type of FSGS?
- What are the chances of achieving remission with these new drugs versus standard care?
This question is drawn from common patient questions about Nephrology and answered using cited medical research. We do not provide individualized advice.